LUSZ Treatment Efficacy in Hospitalized COVID-19 Patients
Status:
RECRUITING
Trial end date:
2025-12-30
Target enrollment:
Participant gender:
Summary
This study aims first to assess the efficacy, safety, and effectiveness of the LUSZ COVID-19 therapy consisting of a comparative study of three different treatment approaches: antiviral, antiretroviral, and immunosuppressive IL-6 receptor antagonist, and second to identify high-risk factors and biomarkers associated with fatal outcomes in hospitalized COVID-19 patients. The study seeks to validate a novel predictive scoring model for disease progression and evaluate the impact of these treatments on mortality, admission to the intensive care unit (ICU), and time to recovery.
Phase:
PHASE1
Details
Lead Sponsor:
Lebanese University
Collaborator:
Hospital Saydet Zgharta University Medical Center
Treatments:
Lopinavir lopinavir-ritonavir drug combination remdesivir tocilizumab